Head-to-head · Cost-Efficiency Index
Teleios Health vs Enhanced
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Teleios Health
Shoppers comfortable calling or messaging before committing, since public pricing detail is minimal.
Visit Teleios HealthEnhanced
Shoppers who want a low starting price on compounded semaglutide or tirzepatide and are comfortable confirming the dose-level price after checkout.
Visit EnhancedThe verdict
Teleios Health and Enhanced tie on the Cost-Efficiency Index at 65/100, so neither wins outright on the numbers, so choose on fit. Teleios Health: Shoppers comfortable calling or messaging before committing, since public pricing detail is minimal. Enhanced: Shoppers who want a low starting price on compounded semaglutide or tirzepatide and are comfortable confirming the dose-level price after checkout.
Worth knowing either way: CoreAge Rx is one of our partners and leads our leaderboard, where partners are listed first (Cost-Efficiency Index 94/100). See how it stacks up: CoreAge Rx vs Teleios Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Teleios Health | Enhanced |
|---|---|---|
| Cost-Efficiency Index | 65/100 | 65/100 |
| Semaglutide / mo | $99/moAll doses, compounded | $89/moStarting price, compounded |
| Tirzepatide / mo | Not disclosed | $129/moStarting price, compounded |
| Semaglutide / yr (modeled) | $1,188 | $1,068 |
| Tirzepatide / yr (modeled) | — | $1,548 |
| Coverage | Coverage not published | Not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #209 | #213 |
Teleios Health
65/100Where the value is
- Advertises a low $99/mo headline starting price, undercutting most compounded-GLP-1 competitors on paper
- Explicitly brands itself as 'physician-led,' setting an expectation of clinician oversight
- Discloses the standard compounded-medication FDA disclaimer up front rather than burying it
The tradeoffs
- No dose amount, drug, or inclusion breakdown is published for the $99/mo figure
- No visit fee, membership fee, or shipping fee disclosure
Enhanced
65/100Where the value is
- Starting prices are on the product pages before checkout: semaglutide from $89 a month, tirzepatide from $129
- The monthly price includes the medication, clinician review and follow-ups
- Microdose plans start at $59 a month for semaglutide and $79 for tirzepatide
The tradeoffs
- Both prices are "starting at" figures, and the price at higher doses isn't published
- No list of the states it serves; its terms point to the partner telehealth platform for that
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.